1. Home
  2. ADM vs ILMN Comparison

ADM vs ILMN Comparison

Compare ADM & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Archer-Daniels-Midland Company

ADM

Archer-Daniels-Midland Company

HOLD

Current Price

$57.88

Market Cap

30.4B

ML Signal

HOLD

Logo Illumina Inc.

ILMN

Illumina Inc.

HOLD

Current Price

$135.12

Market Cap

18.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADM
ILMN
Founded
1902
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Packaged Foods
Medical Specialities
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
30.4B
18.9B
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
ADM
ILMN
Price
$57.88
$135.12
Analyst Decision
Hold
Hold
Analyst Count
6
16
Target Price
$55.67
$117.31
AVG Volume (30 Days)
2.6M
1.6M
Earning Date
02-03-2026
02-05-2026
Dividend Yield
3.52%
N/A
EPS Growth
N/A
N/A
EPS
2.46
4.46
Revenue
$83,211,000,000.00
$4,288,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$4.44
$2.24
P/E Ratio
$23.52
$30.25
Revenue Growth
N/A
N/A
52 Week Low
$40.98
$68.70
52 Week High
$65.00
$153.06

Technical Indicators

Market Signals
Indicator
ADM
ILMN
Relative Strength Index (RSI) 43.38 61.86
Support Level $57.29 $132.93
Resistance Level $58.10 $138.80
Average True Range (ATR) 1.13 3.96
MACD -0.12 -0.42
Stochastic Oscillator 19.30 70.39

Price Performance

Historical Comparison
ADM
ILMN

About ADM Archer-Daniels-Midland Company

Archer-Daniels-Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. The company is also one of the largest grain merchandisers through its extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients and is a large producer of corn-based sweeteners, starches, and ethanol.

About ILMN Illumina Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Share on Social Networks: